Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE versus REVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE versus REVIA.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs REVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Naltrexone is a mu-opioid receptor antagonist that competitively binds to opioid receptors, blocking the effects of endogenous and exogenous opioids. It also exhibits some antagonistic activity at kappa and delta opioid receptors.
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
50 mg orally once daily
None Documented
None Documented
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Terminal half-life of naltrexone is approximately 4 hours; its active metabolite, 6β-naltrexol, has a half-life of about 13 hours. Clinically, the prolonged blockade of opioid receptors (up to 72 hours after a single oral dose) is attributed to the metabolite's accumulation and high receptor affinity.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Renal: primarily as unchanged drug and glucuronide conjugates; fecal: minor; approximately 60% of a dose is excreted in urine within 48 hours (with about 20% as unchanged naltrexone and the rest as metabolites, mainly 6β-naltrexol).
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist